General treatment regimens have not changed much in the past 30 years, in part due to the lack of randomized clinical trials. Surgery is the treatment of choice if the<unk>  is determined to be resectable. Curettage is a commonly used technique. The situation is complicated in a patient with a pathological fracture. It may be best to immobilize the affected limb and wait for the fracture to heal before performing surgery. Patients with<unk> s that are not amenable to surgery are treated with radiation therapy. However caution is employed since a majority of recurrent<unk> s with transformations to the malignant sarcoma phenotype have been in patients receiving radiotherapy for their primary benign lesion. Pharmacotherapy for GCTOB, includes bisphosphonates such as Zoledronate, which are thought to induce apoptosis in the MNGC fraction, preventing<unk> -induced osteolysis. Indeed, in vitro studies have shown zoledronate to be effective in killing osteoclast-like<unk> s. More recently, humanized monoclonal antibodies such as Denosumab targeting the RANK ligand have been employed in treatment of GCTOB in a phase II study. This is based on the notion that increased expression of RANK-ligands by stromal<unk> s plays a role in<unk>  pathogenesis.
Giant-cell tumor of bone
Osteomyelitis
Fibrocartilaginous mesenchymoma of bone
Osteoid osteoma
Osteoblastoma
Osteoma cutis
Fibrous dysplasia of bone
Bone cyst